Schizophrenia Clinical Trial
— V-NeSTOfficial title:
Virtual Reality Supported Therapy for the Negative Symptoms of Psychosis
NCT number | NCT03995420 |
Other study ID # | 260511 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 15, 2019 |
Est. completion date | April 30, 2021 |
Verified date | December 2019 |
Source | Institute of Psychiatry, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Negative symptoms are typically observed in people with schizophrenia and
indicate a loss or reduction of a normal function (e.g. reduced motivation and affect
display). Despite being important predictors of people's recovery the development of
interventions for negative symptoms received only very limited attention. There are currently
no evidenced based therapies for these symptoms.
Aims: To test the feasibility and acceptability of a novel virtual reality assisted therapy,
called Virtual Reality Supported Therapy for the Negative Symptoms of Psychosis (V-NeST).
Methods: This is a single (rater) blind randomised study with two conditions; V-NeST plus
treatment-as-usual (TAU) vs. TAU alone. The study will recruit people with psychosis from NHS
community care teams (in England). Assessments will be at baseline and 3-month
post-randomisation. A nested qualitative study to identify the key themes associated with the
acceptability of the overall study and intervention will be conducted. The study will assess
key feasibility parameters such as: consent and availability for screening; eligibility;
availability for assessment, randomisation and treatment retention. Acceptability will be
assessed by considering: therapy session attendance and drop-out; in-depth feedback from
service users interviews; acceptability of the research procedures and measures.
Participants will be assessed with measures of functioning levels and, negative symptoms .
Analyses will evaluate the feasibility and analyses of clinical outcomes will be focused on
descriptive statistics and confidence intervals for treatment effects. Population variances
of the main outcomes will be estimated for future power calculations. A semi-structured
interview will explore participants' experience of being recruited to the study, receiving
V-NeST and identify barriers (and potential solutions) to treatment engagement.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | April 30, 2021 |
Est. primary completion date | March 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Service users currently under the care of NHS psychosis services; - Aged over 18; - in a stable clinical condition (as judged by primary clinician) - with a documented episode of psychosis and/or a diagnosis of schizophrenia. Exclusion Criteria: - Recent antipsychotic medication change (i.e. in the last 3 weeks); - Moderate to severe learning disability - Insufficient English for therapy - Organic impairment. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Institute of Psychiatry, King's College London | London |
Lead Sponsor | Collaborator |
---|---|
Institute of Psychiatry, London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the Goal Attainment Scale | Measure assessing to degree of participant's individual goals achievement Full description of the measure and scoring can be obtained from the reference below: Logan TK. Goal Attainment Scaling - Applications, Theory, and Measurement - Kiresuk,Tj, Smith,a, Cardillo,Je. Contemp Psychol. 1995;40(10):984-5. Baggio L, Buckley DJ. Detecting change in patient outcomes in a rural ambulatory rehabilitation service: the responsiveness of Goal Attainment Scaling and the Lawton Scale. Aust Health Rev. 2016;40(1):63-8. Ng BF, Tsang HW. Evaluation of a Goal Attainment Program using the Goal Attainment Scale for Psychiatric In-patients in vocational rehabilitation. Work. 2000;14(3):209-16. |
12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |